Us Bancorp \De\ Bei Gene, Ltd. Transaction History
Us Bancorp \De\
- $78.3 Billion
- Q2 2025
A detailed history of Us Bancorp \De\ transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Us Bancorp \De\ holds 1,299 shares of BGNE stock, worth $294,496. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,299
Previous 1,084
19.83%
Holding current value
$294,496
Previous $245,000
20.0%
% of portfolio
0.0%
Previous 0.0%
Shares
31 transactions
Others Institutions Holding BGNE
# of Institutions
269Shares Held
32.5MCall Options Held
101KPut Options Held
105K-
Baker Bros. Advisors LP New York, NY8.8MShares$1.99 Billion20.22% of portfolio
-
Primecap Management CO Pasadena, CA5.09MShares$1.15 Billion0.94% of portfolio
-
Capital International Investors Los Angeles, CA4.89MShares$1.11 Billion0.2% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E91.03MShares$234 Million9.68% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.02MShares$231 Million0.03% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...